RxDoctor Payments DataLook up a doctor →

Nicole Vines

Family · Newark, DENPI 1235614439

Payments from drug & device makers

$5,068in general payments, 2019–2025

Across 226 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$504
  • Incyte Corporation$416
  • Novartis$402
  • Karyopharm Therapeutics Inc.$398
  • AstraZeneca$380
  • Sanofi$276
  • plus $3K from 50 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson11$504
Incyte Corporation20$416
Novartis22$402
Karyopharm Therapeutics Inc.11$398
AstraZeneca21$380
Sanofi9$276
Genentech USA, Inc.13$255
E.r. Squibb & Sons, L.L.C.5$193
Gilead8$159
AbbVie8$153
Merck7$135
Secura Bio, Inc.1$106
Lilly USA, LLC6$106
Pfizer6$105
Astellas Pharma US Inc5$95
Genmab U.S., Inc.4$88
Bristol Myers Squibb2$67
Eisai Inc.4$67
Ipsen Biopharmaceuticals, Inc3$62
Kyowa Kirin, Inc.3$55
Morphosys, US Inc.3$55
Takeda Pharmaceuticals U.S.A., Inc.3$54
Bayer3$54
Amgen2$53
Seagen Inc.3$49
AVEO Pharmaceuticals, Inc.3$48
Beone Medicines USA, Inc.2$44
GSK2$38
Apellis Pharmaceuticals, Inc.2$37
Alnylam Pharmaceuticals Inc.2$35
Tersera Therapeutics LLC2$34
Deciphera Pharmaceuticals Inc.2$34
Daiichi Sankyo Inc.2$30
Mirati Therapeutics, Inc.2$29
Jazz Pharmaceuticals Inc.1$29
Beigene USA, Inc.1$28
Rigel Pharmaceuticals, Inc.2$28
EMD Serono, Inc.2$26
G1 Therapeutics, Inc.1$24
Sumitomo Pharma America, Inc.1$22
Blueprint Medicines Corporation1$21
Agios Pharmaceuticals, Inc.1$21
Stemline Therapeutics Inc.1$21
Myovant Sciences Inc.1$21
Boehringer Ingelheim1$21
TG Therapeutics, Inc.1$20
ADC Therapeutics America, Inc.1$20
Springworks Therapeutics, Inc.1$19
Regeneron Healthcare Solutions, Inc.1$19
Pharmacosmos Therapeutics Inc.1$18
Epizyme, Inc.1$17
Array Biopharma Inc1$17
Tolmar Pharmaceuticals, Inc.1$17
Amneal Pharmaceuticals LLC1$17
Puma Biotechnology, Inc.1$14
Taiho Oncology, Inc.1$12

How this compares

$5,068 in reported general payments places this provider in the 90th percentile of 523 family providers in Delaware.

See all family providers in Delaware →

Medicare billing

Part B allowed, 2024
$109,142
Medicare patients
374
Services billed
1,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Newark

See the full list for Delaware →

Where these figures come from

Is this you, or does something look wrong? →